2. Apoptosis
  3. Apoptosis Caspase Bcl-2 Family
  4. Lobaplatin

Lobaplatin  (Synonyms: D-19466)

Cat. No.: HY-105930 Purity: ≥98.0%
COA Handling Instructions

Molarity Calculator

Lobaplatin (D-19466) is a diastereometric mixture of platinum(II) complexe. Lobaplatin arrests cell cycle at G1 and G2/M phase. Lobaplatin induces apoptosis by increasing expressions of caspase and Bax, decreasing expression of Bcl-2. Lobaplatin can be used for research of cancer.

For research use only. We do not sell to patients.

Lobaplatin Chemical Structure

Lobaplatin Chemical Structure

CAS No. : 135558-11-1

Size Price Stock Quantity
Solid + Solvent
10 mM * 1 mL in Water
ready for reconstitution
 USD 375 In-stock
Solution
10 mM * 1 mL in Water USD 375 In-stock
Solid
1 mg USD 110 In-stock
5 mg USD 340 In-stock
10 mg USD 560 In-stock
50 mg USD 1600 In-stock
100 mg   Get quote  
200 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 2 publication(s) in Google Scholar

Lobaplatin Related Antibodies

Top Publications Citing Use of Products

View All Caspase Isoform Specific Products:

View All Isoforms
Caspase 1 Caspase 2 Caspase 3 Caspase 4 Caspase 5 Caspase 6 Caspase 7 Caspase 8 Caspase 9 Caspase 10 Caspase 12 Caspase Caspase 11 Caspase-13

View All Bcl-2 Family Isoform Specific Products:

View All Isoforms
Bcl-2 Bcl-xL Bcl-W Mcl-1 Bfl-1 Bcl-B Bax Bak Bim

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Lobaplatin (D-19466) is a diastereometric mixture of platinum(II) complexe. Lobaplatin arrests cell cycle at G1 and G2/M phase. Lobaplatin induces apoptosis by increasing expressions of caspase and Bax, decreasing expression of Bcl-2. Lobaplatin can be used for research of cancer[1][2][3].

In Vitro

Lobaplatin (D-19466, 0.25-32 μg/mL; 24-72 h) exhibits anti-proliferative activities against esophageal squamous cell carcinoma (ESCC) cell lines[1].
Lobaplatin (0-16 μg/mL; 48 h) induces esophageal squamous cell carcinoma (ESCC) apoptosis and modulates expression of apoptosis-related proteins[1].
Lobaplatin (1.45 μg/mL; 0-48 h; SMMC-7721 cells) arrests cell cycle progression at G1 and G2/M phases in a time-dependent manner[2].
Lobaplatin (1.45 μg/mL; 0-48 h; SMMC-7721 cells) inhibits the mRNA levels of cyclin B, CDK1, and CDC25C phosphatase, down-regulates Rb/E2F complexes and up-regulates of CDK inhibitors[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Lobaplatin Related Antibodies

Cell Viability Assay[1]

Cell Line: KYSE-410 cells and EC-109 cells
Concentration: 0.25, 0.5, 1, 2, 4, 8, 16 and 32 μg/mL
Incubation Time: 24, 48 and 72 hours
Result: Inhibited the growth of KYSE-410 and EC-109 cells in a dose- and time-dependent manner.
Inhibited the clone formation activity of KYSE-410 and EC-109 cells in a dosedependent manner.

Apoptosis Analysis[1]

Cell Line: KYSE-410 cells and EC-109 cells
Concentration: 0.25, 1, 4 and 16 μg/mL
Incubation Time: 48 hours
Result: Increased the percentage of apoptotic cells in a dose-dependent manner.

Western Blot Analysis[1]

Cell Line: KYSE-410 cells and EC-109 cells
Concentration: 0, 1, 4 and 16 μg/mL
Incubation Time: 48 hours
Result: Increased expressions of cleaved-caspase-3, cleaved-caspase-8, cleaved-caspase-9 and Bax, while decreased expression of Bcl-2.

Cell Cycle Analysis[2]

Cell Line: SMMC-7721 cells
Concentration: 1.45 μg/mL
Incubation Time: 0, 24, 36 and 48 hours
Result: Arrested the proportions of G1, S, and G2/M phases in cells were 45.31, 22.88, and 31.81% at 0 h, 59.91, 11.92, and 28.17% at 24 h, 56.89, 2.83, and 40.28% at 36 h, and 53.80, 2.07, and 44.13% at 48 h, respectively.

Western Blot Analysis[2]

Cell Line: SMMC-7721 cells
Concentration: 1.45 μg/mL
Incubation Time: 0, 24, 36 and 48 hours
Result: Down-regulated cyclin B, CDK1, CDC25C, phosphorylated CDK1 (pCDK1), pCDK4, Rb, E2F, and pRb, and up-regulated p53, p21, and p27.
In Vivo

Lobaplatin (5 and 10 mg/kg; i.p.; once a week, for 3 weeks) suppresses tumor growth of esophageal squamous cell carcinoma (ESCC) xenograft[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male BALB/c nude mice (4-6 weeks) with ESCC xenograft[1]
Dosage: Intraperitoneal injection; once a week, for 3 weeks
Administration: 5 and 10 mg/kg
Result: Suppressed tumor volumes in a dose-dependent manner.
Increased expressions of Bax and decreased expressions of Bcl-2.
Clinical Trial
Molecular Weight

397.33

Formula

C9H18N2O3Pt
CAS No.
Appearance

Solid

Color

White to off-white

SMILES

CC1[O-][Pt+2]2([O-]C1=O)[NH2]CC(CC3)C3C[NH2]2
Shipping

Room temperature in continental US; may vary elsewhere.
Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
Solvent & Solubility
In Vitro: 

H2O : 50 mg/mL (125.84 mM; ultrasonic and warming and heat to 60°C; DMSO can inactivate Lobaplatin's activity)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.5168 mL 12.5840 mL 25.1680 mL
5 mM 0.5034 mL 2.5168 mL 5.0336 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  PBS

    Solubility: 100 mg/mL (251.68 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration: mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).
Purity & Documentation

Purity: ≥98.0%

COA (255 KB) HNMR (256 KB) MS (68 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
H2O 1 mM 2.5168 mL 12.5840 mL 25.1680 mL 62.9200 mL
5 mM 0.5034 mL 2.5168 mL 5.0336 mL 12.5840 mL
10 mM 0.2517 mL 1.2584 mL 2.5168 mL 6.2920 mL
15 mM 0.1678 mL 0.8389 mL 1.6779 mL 4.1947 mL
20 mM 0.1258 mL 0.6292 mL 1.2584 mL 3.1460 mL
25 mM 0.1007 mL 0.5034 mL 1.0067 mL 2.5168 mL
30 mM 0.0839 mL 0.4195 mL 0.8389 mL 2.0973 mL
40 mM 0.0629 mL 0.3146 mL 0.6292 mL 1.5730 mL
50 mM 0.0503 mL 0.2517 mL 0.5034 mL 1.2584 mL
60 mM 0.0419 mL 0.2097 mL 0.4195 mL 1.0487 mL
80 mM 0.0315 mL 0.1573 mL 0.3146 mL 0.7865 mL
100 mM 0.0252 mL 0.1258 mL 0.2517 mL 0.6292 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Lobaplatin Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Lobaplatin135558-11-1D-19466D19466D 19466ApoptosisCaspaseBcl-2 Familydiastereometric mixture of platinum(II) complexecell cyclecaspaseBaxesophageal squamous cell carcinomaInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Lobaplatin
Cat. No.:
HY-105930
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

Request for HNMR Report

We have received your request and will respond to you as soon as possible.